Positive data result in positive share price movements – something of a novelty in the current market.
Evaluate Vantage's coverage of the Ash 2021 congress.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.
Little is known about yesterday’s clinical hold on Allogene’s entire pipeline, but chromosomal abnormalities hint at a worst-case scenario.
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Protagonist and Autolus rose on Friday, but there were losses for Curis, Aptose, Forma and Equillium, among others.